Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of GNX 5086 in healthy volunteers

Trial Profile

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of GNX 5086 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2013

At a glance

  • Drugs GNX 5086 (Primary)
  • Indications Myocardial reperfusion injury
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 29 Aug 2013 New trial record
    • 15 Aug 2013 Status changed from not yet recruiting to recruiting. The first volunteer has been enrolled, according to a Congenia media release.
    • 24 Jul 2013 Status changed from planning to not yet recruiting. The clinical trial application (CTA) received approval by local regulatory authorities in the Netherlands on 24 July 2013, according to a Congenia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top